New Leaf Venture Partners | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/New Leaf Venture Partners/Activity

New Leaf Venture Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

14 milestones· JAN 2026 – JUN 2026Show all

Milestone

Edgewise Therapeutics announced the sale of Sevasemten for up to $2.65 billion, strengthening its balance sheet and centering the company on its cardiovascular pipeline.

Edgewise Therapeutics

Edgewise TherapeuticsNew Leaf Venture Partners

nlvpartners.comJUN 1, 2026

JUN 1, 2026

Milestone

Rallybio Corporation and Avenzo Therapeutics announced a merger agreement to advance next-generation oncology therapies, alongside a $215M concurrent private placement.

Rallybio

Avenzo TherapeuticsRallybioNew Leaf Venture Partners

nlvpartners.comJUN 1, 2026

JUN 1, 2026

Milestone

MemorialCare Heart & Vascular Institute became the first hospital in Los Angeles County to offer Cleerly's AI-powered heart disease analysis.

Cleerly

Cleerly New Leaf Venture Partners

nlvpartners.comMAY 20, 2026

MAY 20, 2026

Milestone

Bluesight launched Prism, an AI platform for health systems, debuting with Prism Assistant.

Bluesight

Bluesight New Leaf Venture Partners

nlvpartners.comMAY 12, 2026

MAY 12, 2026

Milestone

Electra Therapeutics announced the first patient dosed in a Phase 1 study of ipsoprubart (ELA026) in T cell malignancies.

Electra Therapeutics

Electra Therapeutics New Leaf Venture Partners

nlvpartners.comMAY 5, 2026

MAY 5, 2026

Milestone

Star Therapeutics received FDA Rare Pediatric Disease and Breakthrough Therapy designations for VGA039 in von Willebrand disease prophylaxis.

Star Therapeutics

Star Therapeutics New Leaf Venture Partners

nlvpartners.comAPR 21, 2026

APR 21, 2026

Milestone

Cleerly's AI-QCT demonstrated high agreement with invasive IVUS in the INVICTUS registry.

Cleerly

Cleerly New Leaf Venture Partners

nlvpartners.comMAR 20, 2026

MAR 20, 2026

Milestone

Arvinas announced positive Phase 1 data for ARV-102 showing greater than 50% LRRK2 degradation in the CSF of Parkinson's disease patients treated for 28 days.

Arvinas

Arvinas New Leaf Venture Partners

nlvpartners.comMAR 18, 2026

MAR 18, 2026

Milestone

Qlaris Bio appointed Fred Guerard, Pharm.D., as President and Chief Executive Officer.

Qlaris Bio

Qlaris BioNew Leaf Venture Partners

nlvpartners.comMAR 10, 2026

MAR 10, 2026

Milestone

Rallybio Corporation and Candid Therapeutics announced a merger agreement.

Rallybio

Candid TherapeuticsRallybioNew Leaf Venture Partners

nlvpartners.comMAR 2, 2026

MAR 2, 2026

Milestone

Havas Health and BrightInsight forged an exclusive alliance to tackle pharma's $500B+ patient adherence problem.

BrightInsight

BrightInsight New Leaf Venture Partners

nlvpartners.comFEB 26, 2026

FEB 26, 2026

Milestone

TigerConnect launched an AI-powered Operator Console to modernize hospital communications.

TigerConnect

TigerConnect New Leaf Venture Partners

nlvpartners.comFEB 23, 2026

FEB 23, 2026

Milestone

Flosonics Medical received a Vizient Innovative Technology contract for its FloPatch wearable Doppler ultrasound.

Flosonics Medical

Flosonics Medical New Leaf Venture Partners

nlvpartners.comJAN 6, 2026

JAN 6, 2026

Milestone

Aetna approved coverage for Cleerly's AI cardiovascular imaging analysis.

Cleerly

Cleerly New Leaf Venture Partners

nlvpartners.comJAN 6, 2026

JAN 6, 2026